Pirodavir — CAS 124610-07-9

Pirodavir is an antiviral compound that belongs to the class of capsid-binding antiviral agents. It acts by binding to the hydrophobic pocket of rhinovirus VP1 capsid protein, preventing viral attachment and uncoating. It was investigated as a nasal spray for prevention and treatment of common cold caused by rhinoviruses. Mediocon Inc manufactures Pirodavir API at its GMP-certified facility in Aurangabad, Maharashtra, India.

• Prophylaxis and treatment of rhinovirus-induced common cold
• Research into picornavirus inhibitors and antiviral mechanisms
• Investigational treatment for rhinovirus-associated asthma exacerbations
• Study of capsid-binding antiviral compounds

• GMP Certified manufacturing facility in Aurangabad, Maharashtra, India
• Full pharmacopoeial compliance: IP / BP / USP standards
• Complete documentation: Certificate of Analysis (CoA), MSDS, Certificate of Origin
• Stringent in-process quality control at every manufacturing stage
• HPLC purity testing and spectroscopic identification (IR, NMR)
• Cold-chain and controlled-environment storage facilities available
• Exported to 40+ countries with full regulatory support